[Federal Register Volume 87, Number 119 (Wednesday, June 22, 2022)]
[Notices]
[Page 37309]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-13290]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-05-2022]


Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware; Authorization 
of Production Activity; AstraZeneca Pharmaceuticals, LP (Pharmaceutical 
Products), Newark, Delaware

    On February 16, 2022, AstraZeneca Pharmaceuticals, LP submitted a 
notification of proposed production activity to the FTZ Board for its 
facility within Subzone 99D, in Newark, Delaware.
    The notification was processed in accordance with the regulations 
of the FTZ Board (15 CFR part 400), including notice in the Federal 
Register inviting public comment (87 FR 10771, February 25, 2022). On 
June 16, 2022, the applicant was notified of the FTZ Board's decision 
that no further review of the activity is warranted at this time. The 
production activity described in the notification was authorized, 
subject to the FTZ Act and the FTZ Board's regulations, including 
Section 400.14.

    Dated: June 16, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-13290 Filed 6-21-22; 8:45 am]
BILLING CODE 3510-DS-P